CATEGORIES: Research
athena alliance

HNF & Athena Diagnostics Form Strategic Alliance

by | Dec 17, 2018 | 0 comments

Athena Logo

HNF and Athena Diagnostics Form Strategic Alliance

They will Collaborate on Research and Provide Access to Genetic Testing for CMT

We understand that genetic testing can be a daunting journey, especially for patients concerned over high costs, access to testing and the worry that results may have an impact for future insurance. This exciting new partnership aims to relieve the stigma around genetic testing, provide the patient with empowering information regarding a CMT diagnosis, and outline next steps, including information on how a patient may be eligible to participate in research and clinical trials.

The strategic alliance will focus on five key areas:  

  • Providing diagnostic insights via quality genetic testing for participants in HNF’s patient registry, GRIN  
  • Facilitating research discoveries
  • Developing educational material to assist healthcare providers in identifying patients with CMT
  • Generating publications that provide insights into the diagnosis, management, and treatment of CMT, and
  • Encouraging patient enrollment in GRIN to facilitate participation in research and clinical trials

“With a significant pipeline of CMT research initiatives, current clinical trials and the near future of potential treatments, it’s critical that patients know their genotype in order to participate in research and clinical trials. By collaborating with Athena Diagnostics, we will ensure patients have access to affordable testing along with continued education on the importance of genomic testing.” – Allison Moore, Founder and CEO of the Hereditary Neuropathy Foundation

“Our strategic alliance with the Hereditary Neuropathy Foundation marks a milestone for Athena Diagnostics as we continue to provide diagnostic insights for patients living with Charcot-Marie-Tooth disease (CMT). Providing high quality genetic test information is crucial to improving outcomes by identifying appropriate clinical trials and emerging therapies for patients with CMT.” – Shalabh Chandra, Vice President and General Manager, Neurology, Athena

The Hereditary Neuropathy Foundation and Athena Diagnostics are available to help you navigate the complexities of determining what genetic tests to order, decide on the right time for genetic testing, and minimize out-of-pocket costs. Questions? [email protected]

Learn more on this topic

Related Blog Posts

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news